U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
Agios announces that the FDA has accepted its sNDA for mitapivat in sickle cell disease with a Priority Review
Agios announces that the FDA has accepted its sNDA for mitapivat in sickle cell disease with a Priority Review
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.